Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced financial and operational results for the quarter ended September 30, 2014.
“During the third quarter, we continued to advance our key rare disease and oncology programs and remain on track to have our first proof-of-concept data during 2015,” stated Douglas M. Fambrough, Ph.D., Dicerna’s President and CEO. “We continue to expect to initiate a second clinical trial of our lead oncology program DCR-MYC by the end of 2014, and to start clinical development of our lead rare disease program DCR-PH1 in 2015.”
Help employers find you! Check out all the jobs and post your resume.
